High-dose rituximab and anti-MAG-associated polyneuropathy
- PMID: 16534115
- DOI: 10.1212/01.wnl.0000201193.00382.b3
High-dose rituximab and anti-MAG-associated polyneuropathy
Abstract
Rituximab has been administered successfully in patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750 mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials